2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. Carbonic Anhydrase Isoform

Carbonic Anhydrase

 

Carbonic Anhydrase Related Products (150):

Cat. No. Product Name Effect Purity
  • HY-B1056R
    Procodazole (Standard)
    		Inhibitor
    DTA (Standard) is the analytical standard of DTA. This product is intended for research and analytical applications. DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase.
  • HY-B0122S
    Topiramate-13C6
    		Inhibitor
    Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
  • HY-B1480S
    Ethoxzolamide-d5
    		Inhibitor
    Ethoxzolamide-d5 (Redupresin-d5) is deuterium labeled Ethoxzolamide. Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.
  • HY-B0109AS
    Dorzolamide-d3 hydrochloride
    		Inhibitor
    Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-77036R
    Furagin (Standard)
    		Inhibitor
    Furagin (Standard) is the analytical standard of Furagin. This product is intended for research and analytical applications. Furagin (Furazidine) is an analogue of Nitrofurantoin (HY-A0090) and has antibacterial activity. Furagin also inhibits human carbonic anhydrases (Kis: 260 and 57 nM for hCA IX and XII, respectively).
  • HY-B0483R
    Tioxolone (Standard)
    		Inhibitor
    Tioxolone (Standard) is the analytical standard of Tioxolone. This product is intended for research and analytical applications. Tioxolone is an inhibitor of the metalloenzyme carbonic anhydrase I and has anti-acne activity.
  • HY-B0283R
    Acipimox (Standard)
    		Inhibitor
    Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
  • HY-B0553R
    Methazolamide (Standard)
    		Inhibitor
    Methazolamide (Standard) is the analytical standard of Methazolamide. This product is intended for research and analytical applications. Methazolamide (L584601) is a BBB-penatrable and orally active carbonic anhydrase inhibitor, with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage.
  • HY-B0124R
    Zonisamide (Standard)
    		Inhibitor
    Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
  • HY-B0124S2
    Zonisamide-13C6
    		Inhibitor
    Zonisamide-13C6 (AD 810-13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.